{"id":"https://openalex.org/W3097629244","doi":"https://doi.org/10.1080/10428194.2020.1832660","title":"Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K\u03b4 inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)","display_name":"Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K\u03b4 inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)","publication_year":2020,"publication_date":"2020-11-03","ids":{"openalex":"https://openalex.org/W3097629244","doi":"https://doi.org/10.1080/10428194.2020.1832660","mag":"3097629244","pmid":"https://pubmed.ncbi.nlm.nih.gov/33140664"},"language":"en","primary_location":{"id":"doi:10.1080/10428194.2020.1832660","doi":"https://doi.org/10.1080/10428194.2020.1832660","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2020.1832660","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832660?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832660?needAccess=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082720713","display_name":"Morton Coleman","orcid":"https://orcid.org/0000-0002-8516-2513","observed_orcids":["https://orcid.org/0000-0002-8516-2513"]},"institutions":[{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morton Coleman","raw_affiliation_strings":["Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA","institution_ids":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064830159","display_name":"David Belada","orcid":"https://orcid.org/0000-0002-4981-6188","observed_orcids":["https://orcid.org/0000-0002-4981-6188"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"David Belada","raw_affiliation_strings":["4th Department of Internal Medicine \u2013 Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4th Department of Internal Medicine \u2013 Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic","institution_ids":["https://openalex.org/I21250087"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062305482","display_name":"Olivier Casasnovas","orcid":"https://orcid.org/0000-0002-1156-8983","observed_orcids":["https://orcid.org/0000-0002-1156-8983"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Ren\u00e9-Olivier Casasnovas","raw_affiliation_strings":["University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France","institution_ids":["https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074402846","display_name":"R\u00e9my Gressin","orcid":"https://orcid.org/0000-0002-9188-3501","observed_orcids":["https://orcid.org/0000-0002-9188-3501"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I2800555055","display_name":"Centre Hospitalier Universitaire de Grenoble","ror":"https://ror.org/041rhpw39","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055"]},{"id":"https://openalex.org/I4210160510","display_name":"Institut pour l'avanc\u00e9e des biosciences","ror":"https://ror.org/05kwbf598","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I2800555055","https://openalex.org/I4210128919","https://openalex.org/I4210139971","https://openalex.org/I4210150872","https://openalex.org/I4210160510","https://openalex.org/I899635006"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"R\u00e9my Gressin","raw_affiliation_strings":["Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France","Institute for Advanced Biosciences, Inserm U 823, Grenoble, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France","institution_ids":["https://openalex.org/I2800555055"]},{"raw_affiliation_string":"Institute for Advanced Biosciences, Inserm U 823, Grenoble, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210160510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055156255","display_name":"Hui\u2010Peng Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802931750","display_name":"Flinders Medical Centre","ror":"https://ror.org/020aczd56","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2802931750"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Hui-Peng Lee","raw_affiliation_strings":["Flinders Medical Centre, Bedford Park, SA, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Flinders Medical Centre, Bedford Park, SA, Australia","institution_ids":["https://openalex.org/I2802931750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amitkumar Mehta","raw_affiliation_strings":["UAB School of Medicine, Birmingham, AL, USA"],"raw_orcid":"https://orcid.org/0000-0003-0537-4207","affiliations":[{"raw_affiliation_string":"UAB School of Medicine, Birmingham, AL, USA","institution_ids":["https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090442154","display_name":"Javier L Munoz","orcid":"https://orcid.org/0000-0002-9060-8911","observed_orcids":["https://orcid.org/0000-0002-9060-8911"]},"institutions":[{"id":"https://openalex.org/I4387154023","display_name":"Banner MD Anderson Cancer Center","ror":"https://ror.org/049c9q337","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802412784","https://openalex.org/I4387154023"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Javier Munoz","raw_affiliation_strings":["Banner MD Anderson Cancer Center, Gilbert, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Banner MD Anderson Cancer Center, Gilbert, AZ, USA","institution_ids":["https://openalex.org/I4387154023"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111587313","display_name":"Gregor E. G. Verhoef","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Gregor Verhoef","raw_affiliation_strings":["Department of Hematology, University Hospitals Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, University Hospitals Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110914208","display_name":"Claudia Corrado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Claudia Corrado","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071446481","display_name":"Douglas James DeMarini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas J. DeMarini","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022199766","display_name":"Wanying Zhao","orcid":"https://orcid.org/0000-0002-0454-9805","observed_orcids":["https://orcid.org/0000-0002-0454-9805"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wanying Zhao","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108050318","display_name":"Jia Li","orcid":"https://orcid.org/0000-0002-2652-0034","observed_orcids":["https://orcid.org/0000-0002-2652-0034"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jia Li","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109983747","display_name":"Keith C. Fay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087284","display_name":"St Vincent's Hospital Sydney","ror":"https://ror.org/000ed3w25","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210087284"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Keith Fay","raw_affiliation_strings":["Department of Haematology, St Vincent\u2019s Hospital, Darlinghurst, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, St Vincent\u2019s Hospital, Darlinghurst, NSW, Australia","institution_ids":["https://openalex.org/I4210087284"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":13,"corresponding_author_ids":["https://openalex.org/A5109983747"],"corresponding_institution_ids":["https://openalex.org/I4210087284"],"apc_list":null,"apc_paid":null,"fwci":6.4064,"has_fulltext":true,"cited_by_count":41,"citation_normalized_percentile":{"value":0.97526626,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"62","issue":"2","first_page":"368","last_page":"376"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.014600000344216824,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parsaclisib","display_name":"parsaclisib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.9919999837875366},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8560000061988831},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.902999997138977},{"id":"https://openalex.org/keywords/complete-metabolic-response","display_name":"complete metabolic response","score":0.6830000281333923},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7630174160003662},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6280158162117004},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.5186538100242615},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.41682493686676025},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3863835334777832},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27932775020599365},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.20522558689117432},{"id":"https://openalex.org/C191897082","wikidata":"https://www.wikidata.org/wiki/Q11467","display_name":"Metallurgy","level":1,"score":0.06609603762626648}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016403","descriptor_name":"Lymphoma, Large B-Cell, Diffuse","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1080/10428194.2020.1832660","doi":"https://doi.org/10.1080/10428194.2020.1832660","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2020.1832660","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832660?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},{"id":"pmid:33140664","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33140664","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & lymphoma","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:lirias2repo.kuleuven.be:20.500.12942/693999","doi":null,"is_oa":true,"landing_page_url":"https://lirias.kuleuven.be/handle/20.500.12942/693999","pdf_url":"https://lirias.kuleuven.be/retrieve/0da797f9-f2dc-4220-ac78-fa5984ad411c","source":{"id":"https://openalex.org/S7407055369","display_name":"Lirias","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Leukemia & Lymphoma, vol. 62 (2), (368-376)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1080/10428194.2020.1832660","doi":"https://doi.org/10.1080/10428194.2020.1832660","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2020.1832660","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832660?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3097629244.pdf","grobid_xml":"https://content.openalex.org/works/W3097629244.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1969998568","https://openalex.org/W1977635491","https://openalex.org/W1992477322","https://openalex.org/W2050064417","https://openalex.org/W2072646319","https://openalex.org/W2119147717","https://openalex.org/W2147246240","https://openalex.org/W2305142474","https://openalex.org/W2395809727","https://openalex.org/W2479376682","https://openalex.org/W2559431510","https://openalex.org/W2560963837","https://openalex.org/W2744261860","https://openalex.org/W2791299132","https://openalex.org/W2806683542","https://openalex.org/W2895521914","https://openalex.org/W2917721259","https://openalex.org/W2919246217","https://openalex.org/W2970333266","https://openalex.org/W3005797416","https://openalex.org/W3097670697"],"related_works":["https://openalex.org/W2959327776","https://openalex.org/W4389979814","https://openalex.org/W2917721259","https://openalex.org/W4385738741","https://openalex.org/W4213422983","https://openalex.org/W4385975290","https://openalex.org/W4256349944","https://openalex.org/W4394675015","https://openalex.org/W4385295613","https://openalex.org/W4231622124"],"abstract_inverted_index":{"Parsaclisib,":[0],"a":[1,85,106],"potent,":[2],"highly":[3],"selective,":[4],"next-generation":[5],"PI3K\u03b4":[6],"inhibitor,":[7],"was":[8,74,118],"evaluated":[9],"as":[10],"monotherapy":[11,89,125],"in":[12,21,84,115,139],"CITADEL-202":[13],"(NCT02998476),":[14],"an":[15,91],"open-label,":[16],"multicenter,":[17],"phase":[18],"2":[19,34],"study":[20],"patients":[22],"with":[23,129,141],"relapsed":[24],"or":[25],"refractory":[26],"diffuse":[27],"large":[28],"B-cell":[29],"lymphoma.":[30],"Patients":[31],"enrolled":[32],"into":[33],"groups":[35],"(A,":[36],"Bruton":[37],"tyrosine":[38],"kinase":[39],"[BTK]":[40],"inhibitor":[41,48],"na\u00efve,":[42],"n":[43,50],"=":[44,51],"55;":[45],"B,":[46],"BTK":[47],"experienced,":[49],"5)":[52],"received":[53],"oral":[54],"parsaclisib":[55,138],"20":[56,64],"mg":[57,65],"once":[58,66],"daily":[59],"for":[60],"8":[61],"weeks,":[62],"then":[63],"weekly":[67],"while":[68],"deriving":[69],"benefit.":[70],"The":[71],"futility":[72],"boundary":[73],"crossed":[75],"at":[76],"the":[77],"interim":[78],"analysis":[79],"of":[80,96,109,111,137],"Group":[81,116],"A,":[82],"resulting":[83],"negative":[86],"study.":[87],"Parsaclisib":[88,124],"demonstrated":[90,126],"objective":[92],"response":[93,110],"rate":[94],"(ORR)":[95],"25.5%":[97],"(8":[98],"complete":[99,121],"metabolic":[100,103,122],"responses/6":[101],"partial":[102],"responses)":[104],"and":[105,144],"median":[107],"duration":[108],"6.2":[112],"months.":[113],"ORR":[114],"B":[117],"20.0%":[119],"(1":[120],"response).":[123],"manageable":[127],"toxicities":[128],"no":[130],"new":[131],"safety":[132],"signals":[133],"reported.":[134],"Further":[135],"evaluation":[136],"combination":[140],"standard":[142],"therapies":[143],"active":[145],"investigational":[146],"agents":[147],"is":[148],"underway.":[149]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2020-11-09T00:00:00"}